• 1
    Statistics and Information Department. Vital Statistics, 2000. Tokyo: Ministry of Health, Labor and Welfare, 2001.
  • 2
    Jemal A, Siegel R, Ward E et al . Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630.
  • 3
    Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001; 31: 12337.
  • 4
    Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H. Implications of staging in lung cancer. Chest 1997; 112: 242S8S.
  • 5
    Maulik G, Kijima T, Salgia R. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med 2003; 74: 11325.
  • 6
    Cooper CS, Park M, Blair DG et al . Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 2933.
  • 7
    Bottaro DP, Rubin JS, Faletto DL et al . Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 8024.
  • 8
    Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 30925.
  • 9
    Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 126.
  • 10
    Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87: 10639.
  • 11
    Tsao MS, Liu N, Chen JR et al . Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998; 20: 116.
  • 12
    Masuya D, Huang C, Liu D et al . The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004; 90: 155562.
  • 13
    Qiao H, Hung W, Tremblay E et al . Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 2002; 86: 66577.
  • 14
    Inoue T, Kataoka H, Goto K et al . Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 2004; 95: 8038.
  • 15
    Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991; 266: 19 55864.
  • 16
    Union Against Cancer, SobinLH, WittekindC, eds. Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss, 1997.
  • 17
    Travis W, Colby T, Corrin B, Shimosato Y. World Health Organization: Histological Typing of Lung and Pleural Tumors. Berlin: Springer, 1999.
  • 18
    Kim YH, Ishii G, Goto K et al . Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004; 10: 731117.
  • 19
    Takano T, Ohe Y, Sakamoto H et al . Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 682937.
  • 20
    Goto A, Niki T, Moriyama S et al . Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 2004; 54: 67581.
  • 21
    Han SW, Hwang PG, Chung DH et al . Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 10915.
  • 22
    Takanami I, Tanana F, Hashizume T et al . Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996; 53: 3927.
  • 23
    Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 724251.
  • 24
    Olivero M, Rizzo M, Madeddu R et al . Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 18628.
  • 25
    Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 4339.
  • 26
    Ma PC, Jagadeeswaran R, Jagadeesh S et al . Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 147988.
  • 27
    Miyazawa K, Shimomura T, Naka D, Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J Biol Chem 1994; 269: 896670.
  • 28
    Yoshinaga Y, Fujita S, Gotoh M, Nakamura T, Kikuchi M, Hirohashi S. Human lung cancer cell line producing hepatocyte growth factor/scatter factor. Jpn J Cancer Res 1992; 83: 125761.
  • 29
    Nakashiro K, Hara S, Shinohara Y et al . Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol 2004; 165: 53340.
  • 30
    Ma PC, Kijima T, Maulik G et al . c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 627281.
  • 31
    Belfiore A, Gangemi P, Costantino A et al . Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 1997; 82: 23228.
  • 32
    Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 1998; 125: 131524.
  • 33
    Wang R, Kobayashi R, Bishop JM. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci USA 1996; 93: 842530.
  • 34
    Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153: 102334.
  • 35
    Shen X, Kramer RH. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 2004; 165: 131529.
  • 36
    Vadnais J, Nault G, Daher Z et al . Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion. J Biol Chem 2002; 277: 48 34250.
  • 37
    Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 2001; 107: 64354.